VANCOUVER, July 7 /PRNewswire/ -- Neuromed Technologies Inc., a Vancouver-based biopharmaceutical company, today announced it has appointed Dr. Christopher Gallen as President & CEO and a member of the company’s Board of Directors.
In making the announcement on behalf of Neuromed’s Board of Directors, Kurt Wheeler, General Partner at MPM Capital and a member of the Board said, “Dr. Gallen has an extensive track record in clinical development and operations and was instrumental in bringing several drugs to market in central nervous system, sleep and other disorders. We expect that he will lead Neuromed through its next stage of development and help us to capitalize on the full potential of our programs.”
Dr. Gallen was most recently Vice President and Chief of Operations, Clinical Research and Development at Wyeth Research, in charge of global clinical operations including clinical trial management, data management, biostatistics, clinical communications, procedural compliance and training. Prior to Wyeth, Dr. Gallen was VP of Clinical Research at Pharmacia and was responsible for overseeing global CNS development and clinical operations for all specialties and clinical research in the Western Hemisphere.
Previous positions include President of the CRO division at Premier Research Worldwide, where he was a key contributor to a successful IPO, and Senior Director of Medical and Scientific Services at Quintiles International Clinical Research Corporation. Dr. Gallen received his M.D. and Ph.D. from Emory University School of Medicine in Atlanta, Georgia and trained in Psychiatry at Stanford and Neurology at UCSD.
“Neuromed has an outstanding platform with strong potential to lead to medicines that matter for chronic pain and other disorders,” said Dr. Gallen. “This is a superb opportunity to complement Neuromed’s excellent science with first rate development and commercialization. I am excited to join the Neuromed team and contribute my own expertise to NMED-160’s clinical success and in advancing all the company’s rich pipeline programs.”
Ms. Natalie Dakers, who will step down as President & CEO, has taken the company from inception to Phase I human clinical trials and has raised nearly US$50 million in venture capital financing. “Ms. Dakers’ vision and leadership has been instrumental to the financial success and drug development progress of Neuromed,” said Darrell Elliott, Managing Director at MDS Capital and Chairman of Neuromed’s Board of Directors. “We want to express our strong appreciation to Ms. Dakers for her contribution in positioning Neuromed as a world leader in calcium channel drugs.”
About Neuromed Technologies
Neuromed is a private biopharmaceutical company developing the next generation of chronic pain drugs with pipeline programs in anxiety, epilepsy and cardiovascular diseases. Located in Vancouver, Canada, the Company’s drug development programs are designed around validated clinical targets associated with large unmet markets. Neuromed is the only biotech company focused exclusively on calcium channels as drug targets for treatment of neurological diseases.
Corporate Communications Contact: Julie Jang Manager, Communications & Human Resources Neuromed Technologies Inc. Phone: (604) 822-9970 Email: jjang@neuromedtech.com
Neuromed Technologies Inc.
CONTACT: Julie Jang, Manager, Communications & Human Resources, NeuromedTechnologies Inc., Phone: (604) 822-9970, Email: jjang@neuromedtech.com
